Bilaketaren emaitzak - Sachdev Thomas
- Erakusten 1 - 13 emaitzak -- 13
-
1
-
2
Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2 nork Rogério Lilenbaum, Rita Axelrod, Sachdev Thomas, Afshin Dowlati, L. Seigel, Donald G. Albert, Karsten Witt, D. Botkin
Argitaratua 2008Artigo -
3
A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503 nork Anne M. Traynor, Ju-Whei Lee, Gerald K. Bayer, John M. Tate, Sachdev Thomas, Miroslaw Mazurczak, David L. Graham, Jill Kolesar, Joan H. Schiller
Argitaratua 2009Artigo -
4
Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Centr... nork Sherry L. Wolf, Rui Qin, Smitha Menon, Kendrith M. Rowland, Sachdev Thomas, Robert Delaune, Diana L. Christian, Eduardo R. Pajon, Daniel Satele, Jeffrey L. Berenberg, Charles L. Loprinzi
Argitaratua 2010Artigo -
5
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer nork Stephanie L. Hines, Betty A. Mincey, Jeff A. Sloan, Sachdev Thomas, Elaine G. Chottiner, Charles L. Loprinzi, Mark D. Carlson, Philip J. Atherton, Muhammad Salim, Edith A. Perez
Argitaratua 2008Artigo -
6
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer nork Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel, Athanassios Argiris, Marianna Koczywas, Barbara J. Gitlitz, Sachdev Thomas, Igor Espinoza‐Delgado, Everett E. Vokes, David R. Gandara, Chandra P. Belani
Argitaratua 2009Artigo -
7
<i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma nork Minggui Pan, Chen Jiang, Zheyang Zhang, Ninah Achacoso, Stacey E. Alexeeff, Aleyda V. Solorzano, Pam Tse, Elaine Chung, Tilak Sundaresan, Jennifer M. Suga, Sachdev Thomas, Laurel A. Habel
Argitaratua 2023Artigo -
8
Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium nork Nicholas Campbell, Rangesh Kunnavakkam, Natasha B. Leighl, Mark Vincent, David R. Gandara, Marianna Koczywas, Barbara J. Gitlitz, Edem Agamah, Sachdev Thomas, Walter M. Stadler, Everett E. Vokes, Hedy L. Kindler
Argitaratua 2012Artigo -
9
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (... nork Neal Ready, Herbert Pang, Lin Gu, Gregory A. Otterson, Sachdev Thomas, Antonius A. Miller, Maria Q. Baggstrom, Gregory A. Masters, Stephen L. Graziano, Jeffrey Crawford, Jeffrey A. Bogart, Everett E. Vokes
Argitaratua 2015Artigo -
10
<i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer nork Minggui Pan, Chen Jiang, Pam Tse, Ninah Achacoso, Stacey E. Alexeeff, Aleyda V. Solorzano, Elaine Chung, Wenwei Hu, Thach‐Giao Truong, Amit Arora, Tilak Sundaresan, Jennifer M. Suga, Sachdev Thomas, Laurel A. Habel
Argitaratua 2021Artigo -
11
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexp... nork Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Baggstrom, Sachdev Thomas, Ajeet Gajra, Erin M. Bertino, Karen L. Reckamp, Julian R. Molina, Joan H. Schiller, Kisha Mitchell-Richards, Paula N. Friedman, Jon Ritter, Ginger L. Milne, Olwen Hahn, Thomas E. Stinchcombe, Everett E. Vokes
Argitaratua 2017Artigo -
12
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial nork Nitin Jain, Emily Curran, Neil M. Iyengar, Ernesto Díaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark Kirschbaum, Theodore Karrison, Harry P. Erba, Margaret Green, Xavier Poiré, Greg Koval, Kevin Shannon, Poluru L. Reddy, Loren Joseph, Ehab Atallah, Philip A. Dy, Sachdev Thomas, Scott E. Smith, L. Austin Doyle, Walter M. Stadler, Richard A. Larson, Wendy Stock, Olatoyosi Odenike
Argitaratua 2013Artigo -
13
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit nork Scott A. Tomlins, Nickolay A. Khazanov, Benjamin J. Bulen, Daniel H. Hovelson, Melissa J. Shreve, Laura E. Lamb, Marc Matrana, Mark E. Burkard, Eddy S. Yang, William J. Edenfield, Elizabeth Claire Dees, Adedayo A. Onitilo, Michael A. Thompson, Gary L. Buchschacher, Alan M. Miller, Alexander Menter, Benjamin M. Parsons, Timothy R. Wassenaar, Leon C. Hwang, Jennifer M. Suga, Robert D. Siegel, William Irvin, Suresh Nair, Jennifer N. Slim, Jamal Misleh, Jamil Khatri, Gregory A. Masters, Sachdev Thomas, Malek M. Safa, Daniel M. Anderson, Kat Kwiatkowski, Khalis Mitchell, T. Hu-Seliger, Stephanie Drewery, Andrew Fischer, Komal Plouffe, Eric Czuprenski, Jennifer Hipp, Travis Reeder, Hana Vakil, D. Bryan Johnson, Daniel R. Rhodes
Argitaratua 2023Artigo
Bilaketa egiteko lanabesak:
Antzeko gaiak
Internal medicine
Medicine
Cancer
Oncology
Chemotherapy
Confidence interval
Hazard ratio
Lung cancer
Surgery
Gastroenterology
Alternative medicine
Biology
Carboplatin
Cisplatin
Colorectal cancer
Gene
Pathology
Placebo
Clinical endpoint
Cohort
Genetics
Proportional hazards model
Randomized controlled trial
Adverse effect
Allele
Biochemistry
Chemistry
Gain of function
KRAS
Microsatellite